# Tissue nanotransfection and cellular reprogramming in regenerative medicine and antimicrobial dynamics

**Authors:** Mohammed Youssef Shakra

PMC · DOI: 10.3389/fbioe.2025.1558735 · Frontiers in Bioengineering and Biotechnology · 2025-06-18

## TL;DR

Tissue nanotransfection is a non-viral method for in vivo gene delivery and cell reprogramming with potential in regenerative medicine and antimicrobial therapy.

## Contribution

This review introduces tissue nanotransfection as a novel, non-integrative gene delivery platform with high specificity and minimal toxicity.

## Key findings

- TNT enables localized gene delivery and cellular reprogramming using nanoelectroporation.
- TNT shows therapeutic potential in tissue regeneration, wound healing, and antimicrobial applications.
- TNT offers advantages over traditional methods with its non-integrative and low-toxic approach.

## Abstract

Tissue nanotransfection (TNT) is a novel, non-viral nanotechnology platform that enables in vivo gene delivery and direct cellular reprogramming through localized nanoelectroporation. This review synthesizes current advancements in TNT, outlining its device architecture, electroporation principles, and optimized delivery of genetic cargo, including plasmid DNA, mRNA, and CRISPR/Cas9 components. The mechanisms underlying TNT-mediated cellular reprogramming are critically evaluated, including transcriptional activation, epigenetic remodeling, and metabolic shifts, across three major reprogramming strategies—induced pluripotency, direct lineage conversion, and partial cellular rejuvenation. TNT demonstrates transformative therapeutic potential in diverse biomedical applications, including tissue regeneration, ischemia repair, wound healing, immunotherapy, and antimicrobial therapy. This review highlights TNT’s unique advantages over traditional gene delivery systems, namely, its high specificity, non-integrative approach, and minimal cytotoxicity, while also addressing existing limitations such as phenotypic stability and scalability. By integrating emerging data and identifying key translation challenges, this work positions TNT as a conceptual and technological advance in regenerative medicine and targeted gene therapy, offering a roadmap for future research and clinical implementation.

## Full-text entities

- **Diseases:** ischemia (MESH:D007511), cytotoxicity (MESH:D064420)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12213499/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12213499/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12213499/full.md

---
Source: https://tomesphere.com/paper/PMC12213499